The VACO6 xenograft model demonstrates tumor growth inhibition when exposed to anti-RSPO3 alone or in combination with the topoisomerase inhibitor irinotecan or alternatively in combination with nab-paclitaxel (Fig. 1A). Here, RSPO3 is linked to neoplasm.